TY - JOUR
TI - The predictive role for ST2 in patients with acute coronary syndromes and heart failure
AU - Tsigkou, V.
AU - Siasos, G.
AU - Bletsa, E.
AU - Panoilia, M.-E.
AU - Papastavrou, A.
AU - Kokosias, G.
AU - Oikonomou, E.
AU - Papageorgiou, N.
AU - Zaromitidou, M.
AU - Marinos, G.
AU - Vavuranakis, M.
AU - Stefanadis, C.
AU - Papavassiliou, A.G.
AU - Tousoulis, D.
JO - Current Medicinal Chemistry
PY - 2020
VL - 27
TODO - 27
SP - 4479-4493
PB - Bentham Science Publishers
SN - 0929-8673
TODO - 10.2174/0929867326666191016121630
TODO - biological marker;  interleukin 1 receptor;  suppression of tumorigenicity 2;  unclassified drug;  biological marker;  interleukin 1 receptor like 1 protein, acute coronary syndrome;  acute heart failure;  heart failure;  human;  prediction;  prognosis;  protein function;  Review, Acute Coronary Syndrome;  Biomarkers;  Heart Failure;  Humans;  Interleukin-1 Receptor-Like 1 Protein;  Prognosis
TODO - Intensive research has shed light on the utilization of novel biomarkers which fa-cilitate the diagnosis and prognosis of patients with different medical problems. One of the most important biomarkers especially in the spectrum of heart failure is soluble ST2 (sST2: soluble Suppression of Tumorigenicity 2), which is involved in inflammation, fibrosis and cardiac stress. In the revised 2017 ACC/AHA/HFSA, “Focused Update Guidelines for the Management of Heart Failure” ST2 was given a class-IIa recommendation for the optimal risk assessment in patients with heart failure. Many studies indicate that not only baseline but also serial measurements of ST2 can accurately predict future cardiovascular events in pa-tients with Acute Coronary Syndromes and heart failure. Therefore, in this review, we are going to discuss the studies about the prognostic significance of ST2 in patients with Acute Coronary Syndromes, acute and chronic heart failure. © 2020 Bentham Science Publishers.
ER -